New York — Merck & Co. announced plans on Tuesday to implement significant cost reductions totaling $3 billion by the end of 2027. This strategic initiative aims to funnel finances back into the company’s drug pipeline and upcoming product launches.

The plan is essential for Merck as it braces for a potential decline in revenue following the anticipated patent expiration of its top-selling cancer medication, Keytruda, in 2028. The pharmaceutical giant, like many of its peers, is also preparing for upcoming tariffs on imported drugs, which have prompted increased investments to bolster domestic manufacturing capabilities.

CEO Rob Davis emphasized the importance of this multiyear optimization initiative, noting it will allow the company to channel resources from its more established divisions into emerging growth areas. “This transformation of our portfolio will drive our next chapter of innovation-driven growth,” Davis stated.

As part of the restructuring program initiated in July, Merck plans to eliminate various administrative, sales, and research roles. However, the company will offset these losses by hiring in growth sectors. Additional measures include a reduction in its global real estate holdings and a streamlined manufacturing network. The company’s restructuring is expected to yield about $1.7 billion in annual savings by 2027, with pretax restructuring costs projected to reach approximately $3 billion.

In its second-quarter earnings report, Merck fell short of Wall Street expectations for revenue, marking the first such miss since April 2021. While sales of Keytruda showed a modest 9% increase, concerns lingered regarding performance in China regarding Gardasil, the HPV vaccine. Merck has suspended shipments of Gardasil to China, a decision that will extend through at least mid-2025 due to ongoing inventory issues and low demand.

Merck has revised its financial outlook for 2025, now expecting adjusted earnings between $8.87 and $8.97 per share, slightly adjusting its previous estimate. Revenue projections have likewise been narrowed to between $64.3 billion and $65.3 billion.

During the second quarter, the company reported earnings of $2.13 per share, excluding restructuring charges, compared to expectations of $2.01. Total revenue for the quarter reached $15.81 billion, a decline of 2% from the same period last year.

The pharmaceutical division drove sales of approximately $14.05 billion, with Keytruda alone contributing about $7.96 billion. Despite an upward trajectory in some of its offerings, Gardasil’s sales plunged 55% year-over-year to $1.13 billion, highlighting specific vulnerabilities in the Chinese market. Additionally, the younger drug Winrevair, designed for a rare lung condition, brought in $336 million during the quarter, exceeding analyst expectations.

Merck’s animal health sector fared better, achieving nearly $1.65 billion in sales, an 11% rise attributed to heightened demand for livestock products and contributions from newly acquired businesses. As Merck navigates these challenges and opportunities, the company remains committed to innovation and reshaping its strategic focus.